Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Meningeal Carcinomatosis × tucatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 13 Neoplasms 3 Meningeal Neoplasms 3 Colorectal Neoplasms 3 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Rectal Neoplasms 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Colonic Neoplasms 2 Brain Neoplasms 2 Pathologic Complete Response 1 Neoplasm Metastasis 1 Metastatic Breast Cancer With a Isolated Brain Progression 1 Meningeal Carcinomatosis 1 Hemangiosarcoma 1 HER2-positive Gastric Cancer 1 HER2-positive Breast Cancer 1 Gallbladder Neoplasms 1 Esophageal Neoplasms 1 Cholangiocarcinoma 1 Adenocarcinoma Of Esophagus 1 Adenocarcinoma 1

Interventions

Pemetrexed 5 Bevacizumab 5 osimertinib 3 Temozolomide 3 trastuzumab deruxtecan 2 aflutinib 2 Topotecan 2 Spinal Puncture 2 Specimen Handling 2 Radiotherapy, Intensity-Modulated 2 Methotrexate 2 Magnetic Resonance Spectroscopy 2 tucatinib 1 trioctyl phosphine oxide 1 pembrolizumab 1 nimotuzumab 1 merphos 1 lenvatinib 1 glutathione pegylated liposomal doxorubicin 1 epothilone B 1 envafolimab 1 camrelizumab 1 Trastuzumab 1 Transplantation, Autologous 1 Radiotherapy 1 Radiosurgery 1 Nivolumab 1 Ipilimumab 1 Etoposide 1 Erlotinib Hydrochloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05800275 2025-11-18

ETIC-LM

UNICANCER

Phase 2 Recruiting

Meningeal Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡